Form 4: Supernus CMO Rubin Reports Stock Transactions

Supernus Pharmaceuticals' CMO Jonathan Rubin reported the settlement of performance share units and a related stock disposition for tax purposes.

Summary

• Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, Inc. (SUPN), reported transactions on September 25, 2025.
• Acquired 1,875 shares of common stock upon the settlement of Performance Share Units (PSUs) that were granted on February 22, 2024.
• Disposed of 840 shares of common stock at a price of $46.21 per share to satisfy tax withholding requirements in connection with the PSU vesting.
• Beneficial ownership of common stock following these reported transactions is 11,015 shares.
• The performance objectives for the awarded PSUs were established on June 24, 2024.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event involving the vesting of performance share units and subsequent tax-related share disposition, which is a neutral to slightly positive event for the executive and company performance.

Positives

• Jonathan Rubin acquired 1,875 shares of common stock through the settlement of Performance Share Units, indicating the successful achievement of individual performance objectives.

Negatives

• 840 shares of common stock were disposed of to cover tax withholding obligations, resulting in a reduction of the net shares received by the reporting person.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transactions represent a routine executive compensation event with minimal direct impact on the company's overall share structure or valuation.
• Employees: Reflects standard executive compensation practices tied to performance objectives.

Key Dates

Recommendation

The filing details a routine executive compensation event involving the vesting of performance share units and subsequent tax-related share disposition. This type of transaction is standard and does not provide new information that would significantly alter the investment thesis for Supernus Pharmaceuticals, Inc. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell based solely on this information.

Keywords

Supernus, SUPN, Form 4, Insider Transaction, Executive Compensation, Performance Share Units, Jonathan Rubin, Stock Transaction